Document ID: chunk:federal_register_of_legislation:F2024L01327:front:0:p3
Version: federal_register_of_legislation:F2024L01327
Segment Type: other
Provision Reference: 
Character Range: 6034–9433

at least 2 years before clinical onset;
 2.           having received a burn from an electric welding device on at least 10 occasions at the affected site, at least 10 years before clinical onset;
 3.           having PUVA therapy, where:
         1.           the first PUVA treatment commenced at least 5 years before clinical onset; and
         2.           at least 50 PUVA treatments were administered before clinical onset;
Note: PUVA therapy is defined in the Schedule 1 - Dictionary.
 1.           having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the affected site at least 10 years before clinical onset;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
 1.           undergoing a course of radiotherapy for cancer at the affected site, at least 5  years before clinical onset;
 2.           undergoing a course of radiotherapy for acne at the affected site, at least 5 years before clinical onset;
 3.       being infected by the same human papillomavirus type 16, 18 or 33 for at least 2 consecutive years before clinical onset of squamous cell carcinoma of the penis, vulva or perianal skin;
 4.       being infected with human immunodeficiency virus before clinical onset;
 5.       undergoing solid organ (excluding corneal transplant) or bone marrow transplantation at least 5 years before clinical onset;
 6.       taking one of the following medications within the 10 years before clinical onset:
         1.           acalabrutinib;
         2.           azathioprine;
         3.           ciclosporin;
         4.           elotuzumab;
         5.           fingolimod
         6.            hydroxycarbimide (hydroxyurea);
         7.           ibrutinib;
         8.           methotrexate;
         9.             mycophenolate;
        10.             ruxolitinib;
        11.           siponimod
        12.             sirolimus;
        13.         tacrolimus;
        14.           tofacitinib;
        15.           upadacitinib;
        16.           ustekinumab;
        17.           zanubrutinib;
        18.            tumour necrosis factor-α inhibitors adalimumab, certolizumab, etanercept, golimumab, or infliximab; or
        19.            BRAF kinase inhibitors dabrafenib, encorafenib, vemurafenib.
 7.       taking ripretinib within the 10 years before clinical onset of squamous cell carcinoma of the skin;
 8.       taking ozanimod or ponesimod within the 10 years before clinical onset of basal cell carcinoma of the skin;
 9.       taking voriconazole continuously for at least 3 months, at least 6 months before clinical onset of squamous cell carcinoma of the skin
10.       taking a cumulative dose of at least 25 g of hydrochlorothiazide, at least 6 months before clinical onset of squamous cell carcinoma of the skin;
11.       taking a cumulative dose of at least 50 g of hydrochlorothiazide, at least 6 months before clinical onset of basal cell carcinoma of the skin;
12.       having autoimmune hepatitis at the time of clinical onset;
13.       having inflammatory bowel disease at the time of clinical onset;
14.       having psoriasis at the time of clinical onset;
15.       having rheumatoid arthritis at the time of clinical onset;
16.       having sarcoidosis at the time of clinical onset;
17.       having chronic osteomyelitis with a sinus tract draining to the